White Papers
March 22, 2024

Adding (Ultra-) Rare Disease Products to Your Company’s Portfolio: It’s a Whole New “Ball Game”

Interest in rare disease (RD) therapies continues to rise, with many established companies incorporating RD therapies into their portfolios for the first time. This paper:

  • Describes the special challenges associated with distributing RD products
  • Outlines the key steps and deliverables for developing and implementing supply chains for RD therapies
  • Summarizes the pitfalls that biopharma companies must avoid when working to establish reliable supply chains in rare diseases.
Loading...
Consent(Required)

White Papers
September 27, 2023

Ensuring a Reliable Biopharmaceutical Supply in the EU – White Paper

A combination of economic and regulatory factors are driving up the cost and complexity of biopharma supply chains in the EU. This paper explores those factors and outlines both “upstream” and “downstream” strategies that pharma and biotech companies can use to better manage cost, complexity, and risk.

Loading...
Consent(Required)

White Papers
October 27, 2022

Webinar Summary – Supply Chains for Cell and Gene Therapies

Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common.  However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.

On October 20, 2022, AIM conducted a webinar on how companies can orchestrate successful supply chains for ATMPs.  This paper provides a written summary of the webinar discussion.

For a time, webinar registrants can also access a recorded copy of the webinar here.

Loading...
Consent(Required)

White Papers
October 30, 2021

Webinar Summary – Launching a First Product in Europe: The Supply Chain Perspective

On 27 October 2021, AIM hosted a webinar panel discussion that addressed the key supply chain aspects associated with launching a new pharmaceutical or biotech therapy in Europe.

Our panel of experts included:

  • Pim Van Der Aar, Co-Founder & Managing Director, AIM (Moderator)
  • Christian Ellereit, Head of Finance, Europe, Travere Therapeutics
  • Ronald van Zitteren, Principal, AIM
  • Joop Wijdeven, Associate, AIM

The panelists covered supply chain key success factors, best practices, and common pitfalls and mistakes. They also discussed key licensing and legal requirements, as well as the main steps involved in designing and implementing a life science supply chain in Europe. This paper provides a written summary of the webinar.

Loading...
Consent(Required)